A comparison of Taiwan's Industrial Technology Research Institute (ITRI) and Singapore's Agency for Science, Technology and Research (A*STAR) has put two of Asia's most-copied government laboratory systems under the same analytical lens, and the exercise turns on a question R&D managers ask constantly: which technology transfer model actually returns value to the public purse?

The comparison, surfaced through CASRAI's research-administration news feed, frames the two institutes as representative specimens of distinct transfer philosophies rather than as rivals. That distinction matters for portfolio planners who benchmark external partners, because the institutes occupy different positions in their national innovation systems and reward different kinds of industry engagement.

What separates the two models?

ITRI, headquartered in Hsinchu, is the older template. It grew up alongside Taiwan's semiconductor climb and built its transfer practice around industrial consortia, spin-off companies and joint development with manufacturers — a model in which the institute itself often incubates the firm that commercialises the technology. TSMC remains the canonical case: a company that began as an ITRI spin-off and now anchors the global chip supply chain.

ASTAR, by contrast, operates inside Singapore's smaller, more centralised research economy. Its transfer apparatus leans on licensing, research collaborations with multinational corporate labs, and a dense network of public research entities clustered around Biopolis and Fusionopolis. Where ITRI's history favours company creation, ASTAR's administrative design favours contractual research relationships and structured licensing deals.

Why should an R&D manager care?

The choice of partner model changes the paperwork, the budget line and the risk profile.

• Spin-off-driven transfer, the ITRI pattern, places the institute inside the equity story. Industry partners negotiate with a company the institute helped create.
• Licensing-driven transfer, the A*STAR pattern, keeps the institute at arm's length from commercialisation. Partners acquire rights, not co-founders.
• Consortium models spread development cost across multiple firms but dilute exclusivity.
• Contract research offers defined deliverables but limits downstream upside for the sponsor.

None of these structures is superior in the abstract. Each shifts who owns intellectual property, who carries development risk after handoff, and how quickly a result moves from bench to production line.

How solid is the comparison?

Readers should treat any side-by-side of national institutes with caution, and this framing is no exception. Institutes publish their own licensing counts and spin-off tallies, and those figures rarely travel with methodology notes — no sample definitions, no independent audit, no denominator of total research spend. Institute self-reports also tend to emphasise headline successes, the TSMC-style outliers, over the median outcome of a typical licence.

Both institutes are government-funded, which means their incentives align with national economic policy rather than with shareholder returns. That shapes what they count as a successful transfer: jobs created locally, industries seeded, capabilities retained. A corporate R&D manager evaluating a partnership should therefore ask which metric the institute is optimising before assuming the arrangement serves the partner's portfolio goals.

What should partners verify?

Due diligence questions follow directly from the structural differences.

• Which entity holds the background intellectual property, the institute or the spin-off?
• Does the national funding agency hold march-in or reversion rights on the licensed technology?
• What publication and export constraints attach to publicly funded results?
• Is the industrial partner acquiring exclusivity in a defined field, or a non-exclusive right shared with competitors?

The answers differ systematically between a spin-off-heavy system and a licence-heavy one, and they determine the real cost of the collaboration long before the first invoice arrives.

What comes next?

As governments across Asia and Europe re-examine how publicly funded research reaches industry, the ITRI and A*STAR templates will keep serving as reference points, and the next wave of comparisons will need audited transfer data rather than institute-supplied success stories to settle which model delivers.